Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cyclophosphamide
/ therapeutic use
Doxorubicin
/ therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse
/ diagnosis
Prednisone
/ therapeutic use
Prognosis
Psoas Muscles
/ physiopathology
Retrospective Studies
Rituximab
/ therapeutic use
Sarcopenia
/ diagnosis
Sarcopenia
chemoimmunotherapy
diffuse large B-cell lymphoma
prognosis
psoas muscle index
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
pubmed:
11
12
2020
medline:
20
5
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
Muscle mass, defined as the psoas muscle index (PMI), is an important parameter of sarcopenia and it has been shown to be a prognostic factor of non-hematological cancers. This study aimed to investigate the prognostic impact of sarcopenia defined using PMI measurement in patients with diffuse large B-cell lymphoma treated with R-CHOP. We retrospectively investigated the impact of pretreatment PMI on survival and response to treatment. One hundred and twenty patients with DLBCL were included in the study, of whom 65 had baseline sarcopenia according to the defined PMI cutoffs. Sarcopenic patients displayed a worse response to treatment compared with non-sarcopenic patients. In a multivariate analysis, sarcopenia remained predictive of outcomes for overall survival (
Identifiants
pubmed: 33300380
doi: 10.1080/10428194.2020.1856833
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM